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Summary
 
Coligation of CD19, a molecule expressed during all stages of B cell development except plas-
macytes, lowers the threshold for B cell activation with anti-IgM by a factor of 100. The cyto-
plasmic tail of CD19 contains nine tyrosine residues as possible phosphorylation sites and is
postulated to function as the signal transducing element for complement receptor (CR)2. Gen-
eration and analysis of CD19 gene–targeted mice revealed that T cell–dependent (TD) anti-
body responses to proteinaceous antigens were impaired, whereas those to T cell–independent
(TI) type 2 antigens were normal or even augmented. These results are compatible with earlier
complement depletion studies and the postulated function of CD19. To analyze the role of
CD19 in antiviral antibody responses, we immunized CD19
 
2
 
/
 
2
 
 mice with viral antigens of TI-1,
TI-2, and TD type. The effect of CD19 on TI responses was more dependent on antigen dose
and replicative capacity than on antigen type. CR blocking experiments confirmed the role of
CD19 as B cell signal transducer for complement. In contrast to immunization with protein
antigens, infection of CD19
 
2
 
/
 
2
 
 mice with replicating virus led to generation of specific germi-
nal centers, which persisted for 
 
.
 
100 d, whereas maintenance of memory antibody titers as
well as circulating memory B cells was fully dependent on CD19. Thus, our study confirms a
costimulatory role of CD19 on B cells under limiting antigen conditions and indicates an im-
portant role for B cell memory.
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D19 is a 95-kD transmembrane protein of the Ig su-
perfamily. It is specifically expressed on B cells, from
early progenitors in the bone marrow to memory cells, ex-
cept for antibody-forming plasma cells (1). Therefore, it is
used as a major target for immunotherapy approaches to B
cell leukemias (2). CD19 exhibits a highly conserved struc-
ture of two extracellular Ig domains and a 243–amino acid
long cytoplasmic tail with nine tyrosine residues as possible
phosphorylation sites (3, 4). These structural features con-
tribute to its known signaling ability. Upon cross-linking,
CD19 associates with the protein tyrosine kinases lyn (5)
and fyn (6), and signaling via vav/ras/mitogen-activated
protein kinase and the phosphatidylinositol 3-kinase path-
ways are initiated (7). Phospholipase C
 
g
 
 is also activated
(8), leading to the generation of inositol triphosphate (9)
and to Ca
 
2
 
1
 
 mobilization (10).
On mature B cells, CD19 associates in vitro and in vivo
with three different molecules to form a tetrameric com-
plex: CR2 (CD21), target of the antiproliferative antibody
1 (CD81), and Leu-13 (11, 12). These associations have led
to the concept that CD19 is the signal transducer for CR2,
which may not possess intrinsic signaling properties since it
has a short cytoplasmic domain. In addition, CD19 can as-
sociate directly with the B cell receptor (13, 14). CD19 is
necessary for formation of the peritoneal B-1 cell popula-
tion (15–18). Treatment of pregnant mice with an anti-
CD19 antibody led to the loss of B-1 cells in the offspring
(16). This finding correlates with a severe and selective B-1
cell deficiency in CD19
 
2
 
/
 
2
 
 mice (17, 18). In mature B
lymphocytes, CD19 mediates homotypic aggregation (19)
and functions as a B cell costimulator, since coligation of
CD19 lowers the threshold for B cell activation with anti-
IgM antibody by a factor of 100 (20).
Complement, especially its activated component C3d, is
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known to exert B cell costimulatory activity in antibody
responses to T cell–dependent (TD)
 
1
 
 antigens (21) and in
general, under limiting antigen doses (22, 23). This was
shown first by complement depletion experiments with co-
bra venom factor (CVF [24]), later by treatment of mice
with anti-complement receptor (CR) antibodies (25, 26)
or soluble CD21 (27), and most recently by the generation
of C3- and CR2-deficient mice (28–30). We demonstrated
recently that neutralizing IgM antibodies to vesicular sto-
matitis virus (VSV) were mostly complement-independent
except when limiting antigen doses were used. In contrast,
the TD switch to IgG was dependent on complement (31).
Binding of C3 to antigen, which has been demonstrated for
VSV (32), may allow coligation of surface (s)Ig and CR
(“dual antigen recognition” [33]). The recent observation
that immunization with a recombinant hen egg lysozyme
containing one to three C3d domains led to greatly en-
hanced antibody titers (34) suggests an adjuvant function
for C3d (35) and supports this corecognition model.
The generation and analysis of CD19-deficient mice re-
vealed that TD antibody responses and germinal center (GC)
formation were impaired (17, 18). In contrast, antibody ti-
ters to polymeric T cell–independent (TI) type 2 antigens
were normal (17) or even augmented (36). B cell prolifera-
tion upon LPS stimulation was normal in one CD19
 
2
 
/
 
2
 
strain (17) and reduced in the other (18), and IgM titers to
the TI-1 antigen LPS-TNP were reduced (36). Transgenic
mice expressing the human CD19 molecule could comple-
ment the murine CD19 defect and perhaps lead to hyper-
responsiveness (37).
Immunizations with proteinaceous antigens in adjuvant
and live virus infections differ in various respects (38, 39).
Therefore, we wanted to analyze whether the results on
the role of CD19 obtained in in vitro experiments as well
as by immunizations with inert haptenated antigens could
be generalized to models of infection. We used VSV, a
member of the Rhabdovirus family, and lymphocytic
choriomeningitis virus (LCMV), a representative of the
Arenavirus family, as inducer of TI and TD antibody re-
sponses, respectively (40). Replicating and nonreplicating
forms and various application routes were compared, and
the role of complement was studied by CR blocking ex-
periments. Finally, by memory antibody titers, plasma cell
frequencies, memory B cells transfers, and immunohistol-
ogy, we looked for a role of CD19 in B cell memory.
 
Materials and Methods
 
Mice.
 
CD19
 
2
 
/
 
2
 
, Monitor, KINDG, 129Sv, and C57/BL6 mice
were obtained from the breeding colony of the Institut für Labor-
 
tierkunde, Veterinary Hospital (Zurich, Switzerland). Breedings
were performed under specific pathogen–free conditions, whereas
experiments were done in conventional animal facilities. Mice
were used at 8–12 wk of age.
 
Viruses.
 
VSV serotype Indiana (VSV-IND; Mudd-Summers
isolate) was obtained originally from Prof. D. Kolakowsky, Uni-
versity of Geneva (Geneva, Switzerland). It was grown on BHK
cells in MEM supplemented with 5% FCS at 37
 
8
 
C. LCMV (iso-
late WE) had been obtained originally from Dr. F. Lehmann-
Grube, Heinrich Pette Institut für Experimentelle Virologie und
Immunologie, University of Hamburg (Hamburg, Germany). The
recombinant baculoviruses expressing the glycoprotein of VSV
(VSV-G) and the nucleoprotein of LCMV (LCMV-NP) were a
gift from Dr. D.H.L. Bishop, NERC Institute of Virology (Ox-
ford, UK). They were derived from nuclear polyhedrosis virus,
and were grown at 28
 
8
 
C in 
 
Spodoptera
 
 
 
frugiperda
 
 cells in spinner cul-
tures in TC-100 medium (41).
 
CVF and Anti-CR Antibody.
 
Purified CVF (
 
Naja naja
 
) was
obtained from Sigma Chemie (233550; Buchs, Switzerland). We
injected twice 1.2 
 
m
 
g of CVF diluted in 200 
 
m
 
l of balanced salt
solution (BSS) with an interval of 8–10 h, 16 h before immuniza-
tion. The anti-CR antibody 7G6 was a gift of Prof. T. Kinoshita,
Department of Immunoregulation, Research Institute for Microbial
Diseases, Osaka University (Osaka, Japan). It cross-reacts exten-
sively on CR2 and CR1 and induces a downregulation of these
receptors for 
 
z
 
7 d. 200 
 
m
 
g of antibody was diluted in 200 
 
m
 
l of
BSS and injected once intravenously 1 d before immunization (25).
 
Immunizations.
 
For immunizations with live virus or bacu-
lovirus-derived VSV-G (Bac VSV-G), 2 
 
3
 
 10
 
6
 
 PFU of VSV or
10 
 
m
 
g of Bac VSV-G, respectively, were injected in 200 
 
m
 
l of
BSS i.v. or i.p. Alternatively, the same amount of virus or protein
was mixed 1:1 with IFA and then injected subcutaneously at the
base of tail.
Formalin inactivation of VSV-IND was performed by addition
of 16 
 
m
 
l of 4% formalin to 1 ml of VSV-IND at a concentration
of 10
 
9
 
 PFU/ml (final formalin concentration 0.0625% [42]). The
mixture was incubated at 4
 
8
 
C for 16h. Before injection, inacti-
vated virus was diluted with BSS so that 200 
 
m
 
l could be injected
intravenously in every experiment.
 
VSV Neutralization Assay.
 
Neutralizing titers of sera were de-
termined as described (43). In brief, the sera were prediluted 40-
fold in MEM supplemented with 5% FCS, then heat inactivated
for 30 min at 56
 
8
 
C. Serial twofold dilutions were mixed with
equal volumes of VSV diluted to contain 500 PFU/ml. The mix-
ture was incubated for 90 min at 37
 
8
 
C in an atmosphere with 5%
CO
 
2
 
. 100 
 
m
 
l of serum–virus mixture was transferred onto Vero
cell monolayers in 96-well plates and incubated for 1 h at 37
 
8
 
C.
An overlay of 100 
 
m
 
l DMEM containing 1% methylcellulose was
added. After incubation for 24 h at 37
 
8
 
C, the overlay was flicked
off, and the monolayer was fixed and stained with 0.5% crystal vi-
olet. The highest dilution of serum that reduced the amounts of
plaques by 50% was taken as the neutralizing titer. Titers are indi-
cated as 
 
2
 
log
 
2 
 
of 40-fold prediluted sera. To determine IgG titers,
undiluted serum was first pretreated with an equal volume of 0.1 M
2-mercaptoethanol in saline (44).
 
LCMV-NP–specific ELISA.
 
We used a sandwich ELISA with
the following steps: (
 
a
 
) coating with baculovirus-derived LCMV-
NP (1 
 
m
 
g/ml); (
 
b
 
) blocking with 2% BSA (Fluka AG, Buchs,
Switzerland) in PBS; (
 
c
 
) 20-fold prediluted mouse serum, titrated
1:2 over 10 dilution steps; (
 
d
 
) IgM- or IgG-specific horseradish per-
oxidase–labeled goat anti–mouse antibodies (0.5 
 
m
 
g/ml; Southern
Biotechnology Associates, Inc., Birmingham, AL); and (
 
e
 
) substrate
ABTS (2.2
 
9
 
-azino-bis-[3-ethylbenzthiazoline-6-sulfonate]); Boeh-
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; Bac VSV-G,
baculovirus-derived VSV-G; BSS, balanced salt solution; CVF, cobra
venom factor; FDC, follicular dendritic cell; GC, germinal center;
LCMV, lymphocytic choriomeningitis virus; LCMV-NP, LCMV nucle-
oprotein; PNA, peanut agglutinin; RT, room temperature; sIg, surface Ig;
TD, T cell–dependent; TI, T cell–independent; vacc VSV-G, recombi-
nant vaccinia virus expressing VSV-G; VSV, vesicular stomatitis virus;
VSV-G, VSV glycoprotein; VSV-IND, VSV Indiana serotype. 
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ringer Mannheim, Mannheim, Germany) and H
 
2
 
O
 
2
 
 (Fluka AG).
Plates were coated overnight at 4
 
8
 
C; all other incubations were for
60–90 min at room temperature (RT). Between incubations, plates
were washed three times with PBS containing 0.5 ml Tween 20 per
liter. OD was measured at 405 nm in an ELISA reader.
 
Enzyme-linked Immunospot Assay for VSV-specific Antibody-form-
ing Cells.
 
Antibody-forming cell (AFC) frequencies were deter-
mined as described (45, 46). In brief, 25–square well polystyrene
plates were coated with purified VSV (
 
z
 
5 
 
3
 
 10
 
8
 
 PFU/ml). On
the next day, plates were blocked with 2% BSA in PBS (see
ELISA, above) for 2 h. Titrated amounts of spleen or bone mar-
row cells (titration 1:5 over four dilution steps starting with 5 
 
3
 
10
 
6
 
 cells/well) were added in 2% MEM and incubated for 5 h at
37
 
8
 
C. After washing with PBS-Tween (see ELISA, above), goat
anti–mouse IgG antibody (2 
 
m
 
g/ml; E·Y Labs, San Mateo, CA)
was added, and plates were incubated for 2 h at 37
 
8
 
C. After wash-
ing with PBS-Tween, alkaline phosphatase–labeled donkey anti–
goat antibody (1 
 
m
 
g/ml; Jackson ImmunoResearch Labs, West
Grove, PA) was added, and plates were incubated overnight at
RT. On the next day, plates were washed, and the substrate solu-
tion (5-bromo-4-chloro-3-indolyl phosphate at 1 mg/ml in 0.6%
agarose) was added to develop blue color spots. AFC numbers
were then calculated per 10
 
6
 
 nucleated cells.
 
Adoptive Transfer Experiments.
 
Single cell suspensions of sple-
nocytes from VSV-IND–primed normal or CD19
 
2
 
/
 
2
 
 mice were
injected intravenously into irradiated (450 rad) recipients. Donor
cells were pooled from two individuals, and 10
 
7
 
 spleen cells were
transferred to each host (groups of three animals). Recipient mice
were then challenged 24 h after transfer with 2 
 
3
 
 10
 
6
 
 PFU of for-
malin-inactivated VSV. Blood was taken on day 3 after challenge
to determine neutralizing IgG titers.
 
Immunohistochemistry.
 
Freshly removed organs were immersed
in HBSS and snap frozen in liquid nitrogen. Tissue sections of
5-
 
m
 
m thickness were cut in a cryostat, placed on siliconized glass
slides, air dried, fixed with acetone for 10 min, and stored at
 
2
 
70
 
8
 
C. Secondary affinity-purified polyclonal anti-Ig antisera
were diluted in Tris-buffered saline (TBS, pH 7.4) containing 5%
mouse serum. All other dilutions were made in TBS alone. Incu-
bations were done at RT for 30 min; TBS was used for all wash-
ing steps. Alkaline phosphatase was visualized using naphthol AS-
BI (6-bromo-2-hydroxy-3-naphtholic acid-2-methoxy anilide)
phosphate and new fuchsin as substrate. Endogenous alkaline
phosphatase was blocked by levamisole. All color reactions were
performed at RT for 15 min with reagents from Sigma Chemical
Co. (St. Louis, MO). Sections were counterstained with he-
malum. Coverslips were mounted with glycerol and gelatin.
Staining for VSV-specific B cells was done as described (47).
For staining of cell differentiation markers, rehydrated tissue sec-
tions were incubated with the rat primary mAbs anti-FDC (4C11
[48]) and anti-B220 (RA3-6B2; PharMingen, San Diego, CA).
Primary rat mAbs were revealed by a twofold sequential incuba-
tion with rabbit anti–rat Ig and rat alkaline phosphatase anti–alka-
line phosphatase complex (Dakopatts A/S, Glostrup, Denmark).
GCs were stained with peanut agglutinin (PNA [47]).
Figure 1. Antibody responses to replicating and
nonreplicating viral antigens of TI-1, TI-2, and TD
type. (A–D) Mice were immunized intravenously
with either 2 3 106 PFU of live (A) or formalin-
inactivated VSV (B), vacc VSV-G (C), or 10 mg of
Bac VSV-G, and sera for determination of VSV-
neutralizing titers were taken at the indicated time
points. Each data point represents the mean of two
to three mice. (E and F) Mice were immunized
with 200 PFU of live LCMV intravenously (E) or
300 ml of purified LCMV in CFA subcutaneously
(F), and sera were taken on day 16 after immuniza-
tion to test for LCMV-NP–binding antibodies in
ELISA. Each line indicates an individual mouse. All
experiments were done with two to three mice per
group and repeated at least once. Filled symbols,
CD192/2;  open symbols, CD191/1; squares, IgM; cir-
cles, IgG. 
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Results
 
Normal Antibody Titers against Replicating, But Reduced Ti-
ters against Nonreplicating TI-1 or TI-2 VSV-G Antigens.
 
Primary neutralizing antibody responses to four different
forms of VSV-G were tested (Fig. 1, 
 
A
 
–D). VSV-G ex-
posed in a highly repetitive order on live or formalin-inac-
tivated viral particles has been shown to induce neutralizing
IgM responses completely independent of T cells, i.e., as a
TI-1 antigen. In contrast, VSV-G on the membrane of cells
infected with a recombinant vaccinia virus expressing VSV-G
(vacc VSV-G) and Bac VSV-G are TI-2 antigens (49). For
all types of VSV-G antigens, the IgG response is TD (50).
CD192/2 mice immunized with 2 3 106 PFU of live
VSV (Fig. 1 A) or vacc VSV-G (Fig. 1 C) exhibited normal
neutralizing VSV-G–specific antibody titers, although in
the latter case, induction of IgM antibodies was delayed 3 d
compared with control mice. CD192/2 mice survived
these infections normally without displaying any morbidity.
In contrast, antibodies to formalin-inactivated VSV (Fig. 1 B)
and Bac VSV-G protein (Fig. 1 D) were reduced markedly.
This result differs from recent experiments with haptenated
antigens, where the TI-2 response to DNP-Ficoll (36) but
not to NP-Ficoll (17) was enhanced.
TD Anti-LCMV Antibodies Are CD19-dependent for Repli-
cating and Nonreplicating Antigen. Antibodies to LCMV have
been shown to be dependent on T helper cells for the IgM
and IgG response. Therefore, we tested CD192/2 mice for
their capacity to mount LCMV-NP–specific antibodies af-
ter immunization with either live virus intravenously (100
PFU LCMV strain WE; Fig. 1 E) or with UV-inactivated
virus subcutaneously (300 ml of purified LCMV in CFA
corresponding to z20 mg of protein; Fig. 1 F). IgG (Fig. 1,
E and F) as well as IgM (data not shown) to both types of
antigens were decreased when measured in an NP-specific
ELISA. This result confirms the published severe defect of
these mice in TD antibody responses (17, 18). But there is
a striking difference between a low dose of replicating and
a high dose of inactivated virus in CD192/2 mice; only the
latter nonreplicating antigen failed to induce IgG antibod-
ies in CD192/2 mice.
The Route of Antigen Administration Selectively Influences
Antiviral Antibody Responses in CD192/2 Mice. B cell de-
velopment in CD192/2 mice has been shown to be virtu-
ally normal except for a severe reduction of peritoneal B-1
cells (17, 18). To see whether this has any consequence for
antiviral antibodies, we immunized CD192/2 and control
mice with live VSV, formalin-inactivated VSV, or Bac
VSV-G via three different application routes (Table 1): in-
travenously, subcutaneously in IFA, or intraperitoneally. In
the case of Bac VSV-G, the reduction in neutralizing titers
in CD192/2 mice was comparable for all three application
routes, although it was slightly more pronounced after sub-
cutaneous immunization; this indicated that IFA could not
compensate for a CD19-mediated costimulation of B cells.
In contrast, after intraperitoneal immunization with live
or, with a much more pronounced effect, formalin-inacti-
vated virus, neutralizing titers were reduced by a factor of
8–100, suggesting a role for B-1 cells in early anti-VSV im-
mune responses after intraperitoneal infection.
Interactions between CD19 and the Complement System.
To test the hypothesis that CD19 functions as a signal
transducer for CR2, we looked for the ability of CD192/2
mice to produce VSV-specific neutralizing antibodies after
interference with the complement system in two different
Table 1. Dependence of VSV Neutralizing Antibodies on Application Route
Mouse strain: CD191/1 CD192/2
Neutralizing antibody: IgM, day 4 IgG, day 12 IgM, day 4 IgG, day 12
VSV live
i.v. 9/8/8* 12/12/11 9/9/8 12/10/9
s.c. 8/7/7 12/10/9 9/7/4 12/11/8
i.p. 9/8 13/13 7/6/5 10/9/7
VSV form
i.v. 10/9 13/12 7/6/5 10/9/7
i.p. 7/7/6 4/2/1 0/0/0 (day 4) 0/0/0
3/1/1 (day 12)
Bac VSV-G
i.v. 8/8/7 9/9/7 6/5/5 4/3/2
s.c. 6/5 5/4 4/1 1/1
i.p. 8/8/8 9/9/8 7/7/7 8/7/6
*Neutralizing titers are indicated as 2log2 of 40-fold prediluted sera. Each number indicates the titer of an individual mouse. Each experiment was
repeated once or twice.149 Fehr et al.
ways: either the complement component C3 was depleted by
CVF (Fig. 2 A), or the complement receptors CR1 and CR2
were blocked by the mAb 7G6 (Fig. 2 B). Mice were then
immunized with 2 3 106 PFU of formalin-inactivated VSV.
Both treatments led to more pronounced reduction of
IgG than IgM responses, confirming earlier results showing
that VSV activates B cells to produce IgM mostly indepen-
dent of additional signals, whereas switch to IgG depends
on CD41 T cells and complement (31). In addition, Fig. 2
shows that (a) the titers in CD192/2 mice were lower than
in C3-depleted or (less pronounced) in anti-CR–treated
controls, and (b) C3 depletion led to a further reduction in
CD192/2 mice. This second finding suggests that comple-
ment has effects on B cells that are not CD19 mediated, as
for example an opsonizing function of complement for en-
hanced antigen presentation (51). The first finding could be
explained by incomplete blocking of the complement system
with CVF or anti-CR, or it may indicate a direct comple-
ment-independent function of CD19 on B cells. Whether
this needs triggering via a separate potential CD19 ligand is
not known. But direct association of CD19 with sIgM on B
cells has already been demonstrated (13, 14), and may indi-
cate a direct influence on sIg signaling by CD19 (52).
CD19 Is of Crucial Importance for Antiviral B Cell Memory.
More than 20 years ago, an important role of complement
for maintenance of B cell memory was postulated (53) and
later confirmed (54, 55). By opsonization of antigen or im-
mune complexes, complement would either enhance the
persistence of antigen on follicular dendritic cells (FDCs) or
deliver special signals to memory cells via CRs. Since CR2
is thought to transduce signals through CD19, we looked
at B cell memory in CD192/2 and control animals. These
mice were immunized with a standard dose of 2 3 106
PFU of VSV, which is known to induce life-long immu-
nity in mice (47). To assess B cell memory, we chose three
different readouts. (a) First, we looked at maintenance of
neutralizing IgG titers over z100 d after immunization
with live VSV (Fig. 3 A) or Bac VSV-G (Fig. 3 D); after
live VSV infection of CD192/2 mice, neutralizing anti-
body titers dropped from 10 to 2 within 105 d, and after
immunization with Bac VSV-G, they dropped to 1 within
30 and to 0 within 120 d. In both experiments, control an-
imals maintained the titers obtained by day 20 within a fac-
tor of two to four (or within one to two titer steps). (b) As
a readout for memory B cells, we took spleen cells from
animals of the same experiment as in Fig. 3 A at three dif-
ferent time points and adoptively transferred them into ir-
radiated recipient mice. 1 d after transfer, the recipients
were challenged with 2 3 106 PFU of formalin-inactivated
virus, and neutralizing IgG titers 3 d after challenge were
taken as a readout of B cell memory (Fig. 3 B). In control
mice, the memory titers after challenge did not drop signif-
icantly over 105 d, whereas in CD192/2 mice, a signifi-
cantly lower titer than in controls could be measured as
early as day 12. This titer had disappeared completely by
the later time points tested. In a similar experiment (Fig. 3 E),
memory spleen cells were transferred into irradiated trans-
genic recipients expressing the VSV-G either as a soluble
protein in the serum (Monitor [56]) or under a class I pro-
moter on the membrane of most cells (KINDG [57]). The
antigenicity of these transgenes has been shown previously
to restimulate memory B cells (58). Although in Monitor
mice, only CD19-competent cells were able to mount a
small neutralizing titer, in KINDG mice, CD192/2 cells also
produced some neutralizing antibody, but at least 100-fold
lower than control cells. (c) As a readout for VSV-specific
AFCs (Fig. 3 E), enzyme-linked immunospot assays of
bone marrow and spleen cells were performed, again from
animals of the experiment described in Fig. 3 A. Plasma cell
frequencies were determined at three different time points.
Although neutralizing antibody titers in the serum did not
differ between CD192/2 and control mice 12 d after immu-
nization, AFC frequencies in CD192/2 mice were already
lower by a factor of eight in the spleen and almost unde-
tectable in the bone marrow. After 46 and 105 d, AFC
numbers in CD192/2 mice were below the detection level,
whereas in CD19-competent mice, significant numbers of
plasma cells could be measured in spleen and bone marrow
for up to 105 d.
CD19 Is Not Necessary for the Generation of VSV-specific
GCs. A severe defect in the generation of GCs after im-
munization with TD antigens has been described for
CD192/2 (17, 36) as well as C32/2 (59) and CR2/2 mice
(60). Since maintenance of B cell memory is thought to be
governed by persisting antigen in immune complexes on
FDCs in GCs (61), we wanted to see whether the loss of
VSV-specific B cell memory in CD192/2 mice was due to
the failure to generate GCs. From the same mice shown in
Fig. 3, A–C, spleen sections were prepared and stained im-
munohistochemically for VSV-specific B cells (see Materi-
als and Methods, and reference 47; Fig. 4, A and B), GC B
cells (PNA; Fig. 4, C and D), FDCs (4C11; Fig. 4, E and F),
Figure 2. Antibody responses to formalin-inacti-
vated VSV after treatment with CVF or anti-CR
antibody. On day 21, CD192/2 or control mice
were injected twice with CVF (A) or once with
anti-CR antibody 7G6 (B). All mice were then im-
munized on day 0 with 2 3 106 PFU of formalin-
inactivated VSV, and VSV-neutralizing titers were
determined on day 8 (IgM d8) or day 13 (IgG d13).
Each bar represents the mean of two to three mice.
The experiments were repeated once.150 Antiviral B Cell Responses in the Absence of CD19
and total B cells (B220; Fig. 4, G and H). Fig. 4 shows
spleen sections derived from the group of mice killed 46 d
after immunization. Surprisingly, in CD192/2 as well as in
CD19-competent mice, VSV-specific GCs could be ob-
served until day 105; despite this, the former mice lost their
neutralizing antibody titers. Quantitative analysis (Table 2)
showed a difference in numbers of GCs, with the CD192/2
mice about twofold lower than the controls. In addition,
GCs of CD192/2 mice appeared smaller in size (diameter
reduction of z30%). Quantitative analysis of overall GC
numbers yields a reduction of maximally sevenfold [(1.5)3 3
2 5 6.75]. This reduction is substantial, but cannot explain
the total loss of VSV-specific neutralizing antibodies solely
on a quantitative basis. In general, CD19 was apparently
not necessary for generation of antigen-specific GCs to
VSV-G–neutralizing epitopes.
Discussion
The role of CD19 and associated CR2 for costimulation
of B cells has been clearly demonstrated in vitro as well as
with CD192/2 (17, 18) and CR2/2 mice (29, 30) in vivo.
Complement has been postulated to have a bridging role
between innate and adaptive immunity (35). This study
first looked at B cell responses to live virus infections in
CD192/2 mice. Mice were immunized with VSV, which
induces TI-1 IgM antibody response and is controlled by
the subsequent TD IgG response; alternatively, vacc VSV-G
was used, which induces TI-2 antibodies and is controlled
by cytokines and T cells, or LCMV, an Arenavirus that in-
duces strictly TD antibody responses and is controlled by
cytotoxic T cells. CD192/2 mice were protected against all
of these infections and did not show any morbidity. Con-
sistent with published results from studies with haptenated
protein antigens, the TD antibody responses were reduced
markedly. But in contrast to another study (15), TI-2 re-
sponses were not enhanced, and TI-1 responses were only
reduced when nonreplicating antigen was used. This find-
ing may be explained by the following: (a) immunization
with live virus, even if only an abortive replication cycle
occurs, may produce a greater antigen load. This correlates
with published studies that show decreasing dependence of
B cells upon costimulation via complement (and probably
CD19) with increasing antigen dose (22, 23, 31). (b) In
contrast to protein antigens, immunization with live virus
always leads to nonspecific inflammatory reactions and se-
cretion of cytokines (62), among which IFN-a has been
shown to bind to CR2 (63) and to provide survival signals
for GC B cells (64). Whether this mechanism has any rele-
vance during infections needs to be further investigated.
Our results at least indicate that such a stimulation via CR2
would be independent of CD19.
Figure 3. Analysis of B cell memory after VSV in-
fection. CD192/2 and control mice were immunized
with 2 3 106 PFU of live VSV (A) or 10 mg of Bac
VSV-G (D), and neutralizing IgG titers followed
over the indicated time period. On day 12, 46, and
105, spleen and bone marrow cells of two mice from
each group (as in A) were taken and analyzed for fre-
quency of VSV-specific AFCs (C), or spleen cells
were transferred into irradiated recipients, challenged
with inactivated VSV, and assessed for neutralizing
IgG titers 3 d after challenge (B). In another experi-
ment (E), day 30 VSV–immune memory spleen cells
were transferred into VSV-G transgenic Monitor or
KINDG mice, and neutralizing IgG titers were mea-
sured 4 d after transfer. For each time point, two do-
nor mice and three recipient mice were used. The
experiment was performed twice with similar results.151 Fehr et al.
Figure 4. Immunohistochemical staining of memory spleen sections after VSV infection. Spleen sections of the same mice as in Fig. 3, A–C (time
point day 46), were analyzed by immunohistochemistry and stained for VSV-specific B cells (A and B), GC B cells (PNA; C and D), FDCs (4C11; E
and F), and B cells in general (B220; G and H). Original magnifications are z80-fold.152 Antiviral B Cell Responses in the Absence of CD19
CD192/2 animals have a severe defect in the formation
of B-1 B cells, whereas B-2 cells are normal or only slightly
reduced. B-1 cells are thought to produce natural antibod-
ies that may also be involved in autoimmunity (65) as well
as in early defense mechanisms against pathogens. Whether
the absence of CD19 and the defect in peritoneal B-1 cells
have consequences for antiviral immunity was investigated
here by comparing immunizations with VSV via various
infection routes. Indeed, when the virus was given intra-
peritoneally, neutralizing antibody titers were reduced. This
difference was even more drastic when the virus was inacti-
vated. But in the case of live virus infection, it did not have
any effect on protection of CD192/2 animals. These results
may indicate a crucial role of the route of antigen applica-
tion, or they reveal a biological function of the B-1 cell
compartment.
GC formation in CD192/2 mice has been shown to be
severely impaired after immunization with haptenated pro-
tein antigens (17, 36). But consequences for generation of
B cell memory have not been analyzed. These results indi-
cate that memory antibody titers, AFC frequencies, and
memory B cells detected by adoptive transfer are severely
impaired in these mice. Most probably, the generation of
memory B cells is already affected, because—although anti-
body titers 12 d after infection were comparable to control
mice—AFC and memory B cells were already clearly re-
duced at that time. This finding was independent of the
generation of GCs, which could be found in both CD192/2
and control animals, even at .100 d after infection, as de-
scribed for the latter (47). These findings question the strict
correlation between GC formation and establishment or
possibly maintenance of B cell memory (66). GCs are
thought to be the structural environment where somatic
mutation occurs, high-affinity B cells are selected (67), and
potentially autoreactive B cells are eliminated (68). Our re-
sults suggest that GC formation may be necessary but not
sufficient for generation or maintenance of B cell memory.
This supports evidence obtained in earlier studies using
haptenated LPS (69), aged mice (70), or blocking of B7-2
in established GCs, which impaired B cell memory (71).
CD19 may provide additional signals for generation and
survival of memory B cells. Earlier studies that demonstrate
the binding of CD19 to CD77, a marker of GC B cells,
would be in line with this hypothesis (72, 73).
Table 2. Quantitative Analysis of GCs in CD192/2 and Control Mice after Immunization with VSV
Days after
immunization
Mouse
strain
No. of
PNA1 GCs*
No. of
4C111 GCs*
No. of
VSV-specific GCs*
12 CD191/1 32 6 8 27 6 2 15 6 4
CD192/2 27 6 2 21 6 5 10 6 5
46 CD191/1 40 6 6 21 6 7 10 6 3
CD192/2 16 6 1 16 6 15  6  3
105 CD191/1 59 6 2 32 6 37  6  4
CD192/2 25 6 11 16 6 73  6  1
*Numbers 6 SD indicate the amount of GCs counted per 10 visual fields at a magnification of 10.
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